The Surgical Site Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Surgical Site Infections Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Surgical Site Infections Market.

Some of the key takeaways from the Surgical Site Infections Pipeline Report:

• Companies across the globe are diligently working toward developing novel Surgical Site Infections treatment therapies with a considerable amount of success over the years. 
• Surgical Site Infections companies working in the treatment market are Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others, are developing therapies for the Surgical Site Infections treatment 

• Emerging Surgical Site Infections therapies such as – CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others are expected to have a significant impact on the Surgical Site Infections market in the coming years.   
• In January 2023, PolyPid Ltd. provided a positive regulatory update for D-PLEX100 for the prevention of abdominal colorectal surgical site infections (SSIs). Following a recent type D meeting communication with the US Food and Drug Administration (FDA)on the SHIELD I Phase III data, the Company now has clarity regarding the regulatory pathway toward a potential New Drug Application (NDA) submission
• In August 2022, ADVANZ PHARMA Corp. Limited signed an exclusive licensing agreement with PolyPid Ltd. (“PolyPid“), a late-stage bio pharma company aiming to improve surgical outcomes, under which ADVANZ PHARMA receives the exclusive rights for the commercialization of PolyPid’s lead drug candidate, D-PLEX100 for the prevention of surgical site infections (“SSIs”) in abdominal and cardiac surgeries, in Europe
• In December 2020, POLYPID initiated a Phase III, prospective, multinational, multicenter, randomized, controlled, two-arm, double blind study to assess efficacy and safety of D-PLEX administered concomitantly with the standard of care (SoC), compared to a SoC treated control arm, in prevention of post abdominal surgery incisional infection

Surgical Site Infections Overview

Surgical site infections (SSIs) are defined as infections occurring up to 30 days after surgery (or up to one year after surgery in patients receiving implants) and affecting either the incision or deep tissue at the operation site. Despite improvements in prevention, SSIs remain a significant clinical problem as they are associated with substantial mortality and morbidity and impose severe demands on healthcare resources.

Get a Free Sample PDF Report to know more about Surgical Site Infections Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/surgical-site-infections-ssi-pipeline-insight

Emerging Surgical Site Infections Drugs Under Different Phases of Clinical Development Include:

• CS-0003: Covira Surgical
• SBG003: Sonoran Biosciences
• EP 201: Eupraxia Pharmaceuticals
• XF-73: Destiny Pharma
• D-PLEX: POLYPID

Route of Administration

Surgical Site Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Surgical Site Infections Pipeline Therapeutics Assessment

• Surgical Site Infections Assessment by Product Type
• Surgical Site Infections By Stage and Product Type
• Surgical Site Infections Assessment by Route of Administration
• Surgical Site Infections By Stage and Route of Administration
• Surgical Site Infections Assessment by Molecule Type
• Surgical Site Infections by Stage and Molecule Type

DelveInsight’s Surgical Site Infections Report covers around 5+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Surgical Site Infections product details are provided in the report. Download the Surgical Site Infections pipeline report to learn more about the emerging Surgical Site Infections therapies

Some of the key companies in the Surgical Site Infections Therapeutics Market include:

Key companies developing therapies for Surgical Site Infections are – 3M Co., B. Braun SE, Becton Dickinson and Co., bioMerieux SA, Covalon Technologies Ltd., Getinge AB, Johnson and Johnson, Kimberly Clark Corp., Medline Industries Inc., Medtronic Plc, Metall Zug AG, Molnlycke Health Care AB, Paul Hartmann AG, Prescient Surgical, Sotera Health Co., Stryker Corp., STERIS Plc, and Winner Medical Co. Ltd. among others. 

Surgical Site Infections Pipeline Analysis:

The Surgical Site Infections pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Surgical Site Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Surgical Site Infections Treatment.
• Surgical Site Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Surgical Site Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Surgical Site Infections market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Surgical Site Infections drugs and therapies

Surgical Site Infections Pipeline Market Drivers

• Rising number of surgeries and the growing geriatric population, increasing concern about hospital acquired infections along with rising incidences of hospital-acquired infections are some of the important factors that are fueling the Surgical Site Infections Market.

Surgical Site Infections Pipeline Market Barriers

• However, lack of awareness regarding infection control measures, difficulty in identifying the site of infection and other factors are creating obstacles in the Surgical Site Infections Market growth.

Scope of Surgical Site Infections Pipeline Drug Insight    

• Coverage: Global
• Key Surgical Site Infections Companies: Covira Surgical, Sonoran Biosciences, Eupraxia Pharmaceuticals, Destiny Pharma, POLYPID, and others
• Key Surgical Site Infections Therapies: CS-0003, SBG003, EP 201, XF-73, D-PLEX, and others
• Surgical Site Infections Therapeutic Assessment: Surgical Site Infections current marketed and Surgical Site Infections emerging therapies
• Surgical Site Infections Market Dynamics: Surgical Site Infections market drivers and Surgical Site Infections market barriers 

Request for Sample PDF Report for Surgical Site Infections Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services